RVTY
Revvity, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 43.18K | $5.79M | n/a | n/a |
| Q2 2026 | 131 | +9 | 65.85M | $7.33B | +14 | −6 |
| Q1 2026 | 126 | -7 | 72.99M | $6.39B | +4 | −12 |
| Q4 2025 | 133 | 0 | 75.39M | $7.30B | +3 | −2 |
| Q3 2025 | 19 | +1 | 44.69M | $3.92B | +1 | −1 |
| Q2 2025 | 16 | +1 | 42.02M | $4.06B | +3 | −2 |
| Q1 2025 | 12 | -1 | 20.50M | $2.17B | n/a | −1 |
| Q4 2024 | 13 | 0 | 18.11M | $2.02B | +1 | −1 |
| Q3 2024 | 12 | -1 | 11.86M | $1.51B | +1 | −2 |
| Q2 2024 | 13 | n/a | 11.86M | $1.24B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 23.68K | -23.5% | $3.62M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 19.38K | +27.0% | $2.15M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 120 | 0.0% | $17,891 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 495 holders, 115.11M shares, $7.19B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.63K sh · $235,728
Officer · 7.33K sh · $1.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology